Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

The impact of cumulative dosing and premature drug discontinuation (PMDD) of bortezomib (V), thalidomide (T), and dexamethasone (D) on overall survival (OS), event-free survival (EFS), time to next therapy, and post-relapse survival in Total Therapy 3 were examined, using time-dependent methodology,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Rhee, Frits, Szymonifka, Jackie, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Shaughnessy, John D., Hoering, Antje, Crowley, John, Barlogie, Bart
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938233/
https://ncbi.nlm.nih.gov/pubmed/20501894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-01-264333
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados